Temat: "Leflunomide" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Comparative analysis of multiorgan toxicity induced by long term use of disease modifying anti-rheumatic drugs.
Autorzy:: Mumtaz T; Faculty of Science and Technology, Department of Zoology, Government College Women University, Faisalabad, Punjab, Pakistan.
Tahir A; Faculty of Science and Technology, Department of Zoology, Government College Women University, Faisalabad, Punjab, Pakistan.
Tariq MA; Faculty of Science and Technology, Department of Zoology, Government College Women University, Faisalabad, Punjab, Pakistan.
Iqbal MA; Institute of Zoology, University of the Punjab, Lahore, Punjab, Pakistan.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2023 Aug 25; Vol. 18 (8), pp. e0290668. Date of Electronic Publication: 2023 Aug 25 (Print Publication: 2023).
Typ publikacji:: Case Reports; Journal Article
MeSH Terms:: Antirheumatic Agents*/adverse effects
Arthritis, Rheumatoid*/drug therapy
Renal Insufficiency*
Humans ; Methotrexate/adverse effects ; Leflunomide/adverse effects ; Uric Acid ; Creatinine ; Urea

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Therapeutic response to leflunomide in combo therapy and monotherapy is associated to serum teriflunomide (A77 1726) levels.
Autorzy:: Fajardo-Robledo NS; Laboratorio de Investigación y Desarrollo Farmacéutico, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, 44430, Guadalajara, Jalisco, Mexico.
Jacobo-Cuevas H; Programa de Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico.
Perez-Guerrero EE; Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Ciencias Biomédicas, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico.
Corona-Sanchez EG; Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Reumatologia y del Sistema Musculo-Esqueletico, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico.; Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico.
Saldaña-Cruz AM; Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico.
Romero-Tejeda EM; Departamento de Farmacobiologia, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, 44430, Guadalajara, Jalisco, Mexico.
Rodriguez-Jimenez NA; Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico.
Totsuka-Sutto SE; Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico.
Lopez-Roa RI; Laboratorio de Investigación y Desarrollo Farmacéutico, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, 44430, Guadalajara, Jalisco, Mexico.
Ponce-Guarneros JM; Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico.; Instituto Mexicano del Seguro Social, UMF 97, 46474, Magdalena, Jalisco, Mexico.
Alcaraz-Lopez MF; Instituto Mexicano del Seguro Social, HGR 46, 44340, Guadalajara, Jalisco, Mexico.
Cerpa-Cruz S; División de Reumatología, Hospital Civil de Guadalajara 'Fray Antonio Alcalde', Guadalajara, Jalisco, México.
Muñoz-Valle JF; Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Ciencias Biomédicas, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico.
Cardona-Muñoz EG; Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico.
Gonzalez-Lopez L; Programa de Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico. .; Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico. .; Programa de Doctorado en Salud Publica, Departamento de Salud Publica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico. .
Gamez-Nava JI; Programa de Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico. .; Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico. .; Programa de Doctorado en Salud Publica, Departamento de Salud Publica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico. .; Pokaż więcej
Corporate Authors:: Research Group for Factors Related to Therapeutic Outcomes in Autoimmune Diseases
Źródło:: Scientific reports [Sci Rep] 2022 Feb 03; Vol. 12 (1), pp. 1877. Date of Electronic Publication: 2022 Feb 03.
Typ publikacji:: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antirheumatic Agents/*therapeutic use
Arthritis, Rheumatoid/*drug therapy
Crotonates/*therapeutic use
Hydroxybutyrates/*therapeutic use
Leflunomide/*therapeutic use
Nitriles/*therapeutic use
Toluidines/*therapeutic use
Adult ; Aged ; Antirheumatic Agents/adverse effects ; Antirheumatic Agents/blood ; Arthritis, Rheumatoid/blood ; Arthritis, Rheumatoid/diagnosis ; Cross-Sectional Studies ; Crotonates/adverse effects ; Crotonates/blood ; Drug Monitoring ; Drug Therapy, Combination ; Female ; Humans ; Hydroxybutyrates/adverse effects ; Hydroxybutyrates/blood ; Leflunomide/adverse effects ; Leflunomide/blood ; Male ; Middle Aged ; Nitriles/adverse effects ; Nitriles/blood ; Predictive Value of Tests ; Remission Induction ; Severity of Illness Index ; Time Factors ; Toluidines/adverse effects ; Toluidines/blood ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Efficacy of leflunomide in the treatment of palindromic rheumatism.
Autorzy:: Sadri M; Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Esalatmanesh K; Internal Medicine Department, Medical Faculty, Kashan University of Medical Sciences, Kashan, Iran.
Khabbazi A; Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.; Pokaż więcej
Źródło:: International journal of rheumatic diseases [Int J Rheum Dis] 2022 Aug; Vol. 25 (8), pp. 893-896. Date of Electronic Publication: 2022 Jun 06.
Typ publikacji:: Journal Article
MeSH Terms:: Antirheumatic Agents*/adverse effects
Arthritis, Rheumatoid*/diagnosis
Arthritis, Rheumatoid*/drug therapy
Drug Therapy, Combination ; Humans ; Leflunomide/adverse effects ; Methotrexate/adverse effects ; Prednisolone/therapeutic use ; Retrospective Studies ; Treatment Outcome
SCR Disease Name:: Palindromic rheumatism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Outcome of solid and cavitary pulmonary nodules in rheumatoid arthritis patients-case series.
Autorzy:: Aksoy A; Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, Marmara University, İstanbul, Turkey.
Kocakaya D; Department of Pulmonary Medicine and Critical Care, Faculty of Medicine, Marmara University, İstanbul, Turkey.
Yalçınkaya Y; Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, Marmara University, İstanbul, Turkey.
Bozkurtlar E; Department of Basic Sciences, Division of Pathology, Faculty of Medicine, Marmara University, İstanbul, Turkey.
Karakurt S; Department of Pulmonary Medicine and Critical Care, Faculty of Medicine, Marmara University, İstanbul, Turkey.
Eryüksel E; Department of Pulmonary Medicine and Critical Care, Faculty of Medicine, Marmara University, İstanbul, Turkey.
İnanç N; Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, Marmara University, İstanbul, Turkey.; Pokaż więcej
Źródło:: Turkish journal of medical sciences [Turk J Med Sci] 2022 Apr; Vol. 52 (5), pp. 1713-1720. Date of Electronic Publication: 2022 Oct 19.
Typ publikacji:: Journal Article
MeSH Terms:: Arthritis, Rheumatoid*/complications
Arthritis, Rheumatoid*/drug therapy
Arthritis, Rheumatoid*/chemically induced
Antirheumatic Agents*/therapeutic use
Humans ; Leflunomide/therapeutic use ; Retrospective Studies ; Tumor Necrosis Factor Inhibitors ; Methotrexate/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA).
Autorzy:: Mulder MLM; Department of Rheumatology, Sint Maartenskliniek, PO Box 9011, Nijmegen, 6500 GM, The Netherlands. .; Department of Rheumatic Diseases, Radboud University Medical Center, Nijmegen, The Netherlands. .
Vriezekolk JE; Department of Rheumatology, Sint Maartenskliniek, PO Box 9011, Nijmegen, 6500 GM, The Netherlands.
den Broeder N; Department of Rheumatology, Sint Maartenskliniek, PO Box 9011, Nijmegen, 6500 GM, The Netherlands.
Mahler EAM; Department of Rheumatology, Sint Maartenskliniek, PO Box 9011, Nijmegen, 6500 GM, The Netherlands.
Helliwell PS; Leeds Institute of Rheumatology and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
van den Hoogen FHJ; Department of Rheumatology, Sint Maartenskliniek, PO Box 9011, Nijmegen, 6500 GM, The Netherlands.; Department of Rheumatic Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
den Broeder AA; Department of Rheumatology, Sint Maartenskliniek, PO Box 9011, Nijmegen, 6500 GM, The Netherlands.; Department of Rheumatic Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Wenink MH; Department of Rheumatology, Sint Maartenskliniek, PO Box 9011, Nijmegen, 6500 GM, The Netherlands.; Pokaż więcej
Źródło:: Trials [Trials] 2020 Feb 10; Vol. 21 (1), pp. 155. Date of Electronic Publication: 2020 Feb 10.
Typ publikacji:: Clinical Trial Protocol; Journal Article
MeSH Terms:: Antirheumatic Agents/*administration & dosage
Arthritis, Psoriatic/*drug therapy
Immunosuppressive Agents/*administration & dosage
Leflunomide/*administration & dosage
Methotrexate/*administration & dosage
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antirheumatic Agents/adverse effects ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Humans ; Immunosuppressive Agents/adverse effects ; Leflunomide/adverse effects ; Male ; Methotrexate/adverse effects ; Middle Aged ; Quality of Life ; Randomized Controlled Trials as Topic ; Treatment Outcome ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Onychodystrophy following the use of leflunomide for seronegative rheumatoid arthritis.
Autorzy:: Azhar AF; Texas A&M University College of Medicine, Bryan, Texas, USA.
Evanson B; Texas A&M University College of Medicine, Bryan, Texas, USA.; Department of Dermatology, Baylor Scott & White, Temple, Texas, USA.
Parekh PK; Texas A&M University College of Medicine, Bryan, Texas, USA.; Department of Dermatology, Baylor Scott & White, Temple, Texas, USA.; Pokaż więcej
Źródło:: Dermatologic therapy [Dermatol Ther] 2020 Nov; Vol. 33 (6), pp. e14491. Date of Electronic Publication: 2020 Nov 12.
Typ publikacji:: Letter
MeSH Terms:: Antirheumatic Agents*/adverse effects
Arthritis, Rheumatoid*/diagnosis
Arthritis, Rheumatoid*/drug therapy
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Humans ; Leflunomide/adverse effects

Opinia redakcyjna

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Leflunomide monotherapy versus combination therapy with conventional synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: a retrospective study.
Autorzy:: Deng D; Department of Rheumatology, Mianyang Central Hospital, Mianyang, Sichuan, China.
Zhou J; Department of Clinical Research Center, Dazhou Central Hospital, No. 56 Nanyuemiao Street, Tongchuan District, Dazhou, Sichuan, China.
Li M; Department of Rheumatology, Mianyang Central Hospital, Mianyang, Sichuan, China.
Li S; Department of Rheumatology, Mianyang Central Hospital, Mianyang, Sichuan, China.
Tian L; Department of Rheumatology, Mianyang Central Hospital, Mianyang, Sichuan, China.
Zou J; Department of Rheumatology, Mianyang Central Hospital, Mianyang, Sichuan, China.
Wang T; Department of Rheumatology, Dazhou Central Hospital, Dazhou, Sichuan, China.
Wu J; Department of Rheumatology, Dazhou Central Hospital, Dazhou, Sichuan, China.
Zeng F; Department of Clinical Research Center, Dazhou Central Hospital, No. 56 Nanyuemiao Street, Tongchuan District, Dazhou, Sichuan, China. .
Yang J; Department of Rheumatology, Mianyang Central Hospital, Mianyang, Sichuan, China. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2020 Jul 23; Vol. 10 (1), pp. 12339. Date of Electronic Publication: 2020 Jul 23.
Typ publikacji:: Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antirheumatic Agents/*administration & dosage
Arthritis, Rheumatoid/*drug therapy
Hydroxychloroquine/*administration & dosage
Leflunomide/*administration & dosage
Methotrexate/*administration & dosage
Adult ; Aged ; Arthritis, Rheumatoid/blood ; Drug Therapy, Combination ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide.
Autorzy:: Hopkins AM; Sansom Institute for Health Research, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia.
Vitry AI; Sansom Institute for Health Research, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia.
O'Doherty CE; Sansom Institute for Health Research, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia.
Proudman SM; Department of Rheumatology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.; Discipline of Medicine, Adelaide University, Adelaide, South Australia, Australia.
Wiese MD; Sansom Institute for Health Research, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia.; Pokaż więcej
Źródło:: International journal of rheumatic diseases [Int J Rheum Dis] 2017 Nov; Vol. 20 (11), pp. 1795-1797. Date of Electronic Publication: 2015 Jul 14.
Typ publikacji:: Letter
MeSH Terms:: Antirheumatic Agents/*therapeutic use
Arthritis, Rheumatoid/*drug therapy
Biological Products/*therapeutic use
Drug Costs/*trends
Immunosuppressive Agents/*therapeutic use
Leflunomide/*therapeutic use
Practice Patterns, Physicians'/*trends
Antirheumatic Agents/economics ; Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/economics ; Australia ; Biological Products/economics ; Clinical Decision-Making ; Drug Costs/legislation & jurisprudence ; Drug Utilization Review ; Health Expenditures/trends ; Humans ; Immunosuppressive Agents/economics ; Leflunomide/economics ; Practice Patterns, Physicians'/economics ; Practice Patterns, Physicians'/legislation & jurisprudence ; Program Evaluation ; Time Factors ; Treatment Outcome

Opinia redakcyjna

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis: Data from a large real-life cohort.
Autorzy:: Gomides APM; Departamento de Reumatologia, Universidade de Brasília, Brasília, Distrito Federal, Brazil.; Departamento do curso de Medicina, Centro Universitário de Brasília- Uniceub, Brasília, Distrito Federal, Brazil.
de Albuquerque CP; Departamento de Reumatologia, Universidade de Brasília, Brasília, Distrito Federal, Brazil.
Santos ABV; Departamento de Reumatologia, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.
Amorim RBC; Departamento de Reumatologia, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.
Bértolo MB; Departamento de Reumatologia, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil.
Júnior PL; Departamento de Reumatologia, Faculdade de Medicina da Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil.
Santos IA; Departamento de Reumatologia, Faculdade de Medicina da Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil.
Giorgi RDN; Departamento de Reumatologia, Instituto de Assistência Médica ao Servidor Público Estadual, Hospital do Servidor Público Estadual de São Paulo, São Paulo, São Paulo, Brazil.
Sacilotto NC; Departamento de Reumatologia, Instituto de Assistência Médica ao Servidor Público Estadual, Hospital do Servidor Público Estadual de São Paulo, São Paulo, São Paulo, Brazil.
Radominski SC; Departamento de Reumatologia, Universidade Federal do Paraná, Curitiba, Paraná, Brazil.
Borghi FM; Departamento de Reumatologia, Universidade Estadual de Maringá, Maringá, Paraná, Brazil.
Guimarães MFBR; Departamento de Reumatologia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Pinto MRDC; Departamento de Reumatologia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Resende GG; Departamento de Reumatologia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Bonfiglioli KR; Departamento de Reumatologia, Universidade de São Paulo, São Paulo, São Paulo, Brazil.
Silva HCD; Departamento de Reumatologia, Universidade de São Paulo, São Paulo, São Paulo, Brazil.
Sauma MFLDC; Departamento de Reumatologia, Universidade Federal do Pará, Belém, Pará, Brazil.
Sauma ML; Departamento de Reumatologia, Universidade Federal do Pará, Belém, Pará, Brazil.
de Medeiros JB; Departamento de Reumatologia, Universidade Federal do Pará, Belém, Pará, Brazil.
Pereira IA; Departamento de Reumatologia, Universidade Federal de Santa Catarina, Florianópolis, Santa Catarina, Brazil.
de Castro GRW; Departamento de Reumatologia, Universidade do Sul de Santa Catarina- Unisul, Florianópolis, Santa Catarina,Brazil.
Brenol CV; Departamento de Reumatologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
Xavier RM; Departamento de Reumatologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
da Mota LMH; Departamento de Reumatologia, Universidade de Brasília, Brasília, Distrito Federal, Brazil.
Pinheiro GDRC; Departamento de Reumatologia, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2019 Mar 01; Vol. 14 (3), pp. e0213219. Date of Electronic Publication: 2019 Mar 01 (Print Publication: 2019).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antirheumatic Agents/*therapeutic use
Arthritis, Rheumatoid/*drug therapy
Synthetic Drugs/*therapeutic use
Adult ; Antirheumatic Agents/adverse effects ; Arthritis, Rheumatoid/pathology ; Arthritis, Rheumatoid/psychology ; Brazil ; Cross-Sectional Studies ; Female ; Humans ; Leflunomide/adverse effects ; Leflunomide/therapeutic use ; Male ; Medication Adherence ; Methotrexate/adverse effects ; Methotrexate/therapeutic use ; Middle Aged ; Synthetic Drugs/adverse effects ; Treatment Failure

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial.
Autorzy:: Wijesinghe H; Department of Rheumatology, The National Hospital of Sri Lanka, Colombo, Sri Lanka.
Galappatthy P; Department of Pharmacology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka. .; Department of Pharmacology and Pharmacy, Faculty of Medicine, University of Colombo, PO Box 271, Kynsey Road, Colombo 8, Sri Lanka. .
de Silva R; Department of immunology, Medical Research Institute, Colombo, Sri Lanka.
Seneviratne SL; Consultant and Professor in Clinical Immunology and Allergy, Royal Free Hospital, University College London, London, UK.; Department of Surgery, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.
Saravanamuttu U; Department of Rheumatology, The National Hospital of Sri Lanka, Colombo, Sri Lanka.
Udagama P; Department of Zoology, Faculty of Science, University of Colombo, Colombo, Sri Lanka.
Hart M; Immunology Section Imperial College, and Department of Infection & Immunity, London, UK.
Kelleher P; Immunology Section Imperial College, and Department of Infection & Immunity, London, UK.
Senerath U; Department of Community Medicine, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.
Fernandopulle R; Department of Pharmacology, General Sir John Kotelawala Defense University, Colombo, Sri Lanka.
Weerasekera LP; Department of Rheumatology, The National Hospital of Sri Lanka, Colombo, Sri Lanka.
Wijayaratne LS; Department of Rheumatology, The National Hospital of Sri Lanka, Colombo, Sri Lanka.; Pokaż więcej
Źródło:: BMC musculoskeletal disorders [BMC Musculoskelet Disord] 2017 Jul 19; Vol. 18 (1), pp. 310. Date of Electronic Publication: 2017 Jul 19.
Typ publikacji:: Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms:: Antirheumatic Agents/*administration & dosage
Arthritis, Rheumatoid/*blood
Arthritis, Rheumatoid/*drug therapy
Isoxazoles/*administration & dosage
Methotrexate/*administration & dosage
Rituximab/*administration & dosage
Adult ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Humans ; Leflunomide ; Lymphocytes/drug effects ; Lymphocytes/metabolism ; Male ; Middle Aged ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Efficacy and safety of weekly leflunomide for the treatment of early rheumatoid arthritis: a randomized, multi-center study.
Autorzy:: Ren LM; Department of Rheumatology and Immunology, People's Hospital of Peking University, Beijing, China.
Li R; Department of Rheumatology and Immunology, People's Hospital of Peking University, Beijing, China.
Chen LN; Department of Rheumatology, Xijing Hospital, Fourth Military Medical University, Xian, China.
Zhu P; Department of Rheumatology, Xijing Hospital, Fourth Military Medical University, Xian, China.
Gu F; Department of Rheumatology, Nanjing Drum Tower Hospital, Nanjing, China.
Sun LY; Department of Rheumatology, Nanjing Drum Tower Hospital, Nanjing, China.
Zhao JX; Department of Rheumatology, Peking University Third Hospital, Beijing, China.
Liu XY; Department of Rheumatology, Peking University Third Hospital, Beijing, China.
Guo JL; Department of Rheumatology, China-Japan Union Hospital of Jilin University, Changchun, China.
Bi LQ; Department of Rheumatology, China-Japan Union Hospital of Jilin University, Changchun, China.
Hao YJ; Department of Rheumatology, Peking University First Hospital, Beijing, China.
Zhang ZL; Department of Rheumatology, Peking University First Hospital, Beijing, China.
Mei YF; Department of Rheumatology, the First Hospital Affiliated to Harbin Medical University, Harbin, China.
Zhang ZY; Department of Rheumatology, the First Hospital Affiliated to Harbin Medical University, Harbin, China.
Liu HX; Department of Rheumatology, Qi Lu Hospital of Shandong University, Jinan, China.
Li XF; Department of Rheumatology, Qi Lu Hospital of Shandong University, Jinan, China.
Luo Y; Department of Rheumatology, Southwest Hospital, the Third Military Medical University, Chongqing, China.
Fang YF; Department of Rheumatology, Southwest Hospital, the Third Military Medical University, Chongqing, China.
Li ZG; Department of Rheumatology and Immunology, People's Hospital of Peking University, Beijing, China.
Su Y; Department of Rheumatology and Immunology, People's Hospital of Peking University, Beijing, China.; Pokaż więcej
Źródło:: International journal of rheumatic diseases [Int J Rheum Dis] 2016 Jul; Vol. 19 (7), pp. 651-7. Date of Electronic Publication: 2015 Aug 13.
Typ publikacji:: Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:: Antirheumatic Agents/*administration & dosage
Arthritis, Rheumatoid/*drug therapy
Isoxazoles/*administration & dosage
Adult ; Antirheumatic Agents/adverse effects ; Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/immunology ; Blood Sedimentation ; Chi-Square Distribution ; China ; Drug Administration Schedule ; Early Diagnosis ; Female ; Humans ; Isoxazoles/adverse effects ; Leflunomide ; Male ; Middle Aged ; Pain Measurement ; Predictive Value of Tests ; Remission Induction ; Severity of Illness Index ; Time Factors ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: IL-22-producing CD4+T cells in the treatment response of rheumatoid arthritis to combination therapy with methotrexate and leflunomide.
Autorzy:: Zhong W; The First Hospital of Jilin University, Department of Rheumatology, Changchun, 130021, China.
Zhao L; The First Hospital of Jilin University, Department of Rheumatology, Changchun, 130021, China.
Liu T; The First Hospital of Jilin University, Department of Rheumatology, Changchun, 130021, China.
Jiang Z; The First Hospital of Jilin University, Department of Rheumatology, Changchun, 130021, China.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2017 Jan 24; Vol. 7, pp. 41143. Date of Electronic Publication: 2017 Jan 24.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antirheumatic Agents/*therapeutic use
Arthritis, Rheumatoid/*drug therapy
Arthritis, Rheumatoid/*immunology
Interleukins/*immunology
Isoxazoles/*therapeutic use
Methotrexate/*therapeutic use
T-Lymphocytes, Helper-Inducer/*immunology
Adult ; Aged ; Arthritis, Rheumatoid/blood ; Drug Therapy, Combination ; Female ; Humans ; Interleukins/blood ; Leflunomide ; Male ; Middle Aged ; Treatment Outcome ; Interleukin-22

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Clinical course and therapeutic approach to varicella zoster virus infection in children with rheumatic autoimmune diseases under immunosuppression.
Autorzy:: Leuvenink R; University of Basel Medical School, Basel, Switzerland.; Pediatric Rheumatology, University of Basel Children's Hospital, Spitalstrasse 33, CH - 4031, Basel, Switzerland.
Aeschlimann F; University Children's Hospital, Zürich, Switzerland.
Baer W; Department of Pediatrics, Hospital of Chur, Chur, Switzerland.
Berthet G; Department of Pediatrics, Hospital of Aarau, Aarau, Switzerland.
Cannizzaro E; University Children's Hospital, Zürich, Switzerland.
Hofer M; Unité romande de rhumatologie pédiatrique, CHUV, University of Lausanne and HUG, Geneva, Switzerland.
Kaiser D; Department of Pediatrics, Hospital of Lucerne, Lucerne, Switzerland.
Schroeder S; University Children's Hospital, Zürich, Switzerland.
Heininger U; Pediatric Rheumatology, University of Basel Children's Hospital, Spitalstrasse 33, CH - 4031, Basel, Switzerland.
Woerner A; Pediatric Rheumatology, University of Basel Children's Hospital, Spitalstrasse 33, CH - 4031, Basel, Switzerland. .; Pokaż więcej
Źródło:: Pediatric rheumatology online journal [Pediatr Rheumatol Online J] 2016 Jun 02; Vol. 14 (1), pp. 34. Date of Electronic Publication: 2016 Jun 02.
Typ publikacji:: Journal Article; Multicenter Study
MeSH Terms:: Antirheumatic Agents/*therapeutic use
Arthritis, Juvenile/*complications
Chickenpox/*complications
Herpes Zoster/*complications
Immunosuppressive Agents/*therapeutic use
Acyclovir/analogs & derivatives ; Acyclovir/therapeutic use ; Adolescent ; Antiviral Agents/therapeutic use ; Arthritis, Juvenile/drug therapy ; Chickenpox/drug therapy ; Child ; Child, Preschool ; Etanercept/therapeutic use ; Female ; Herpes Zoster/drug therapy ; Humans ; Immunocompromised Host ; Isoxazoles/therapeutic use ; Leflunomide ; Male ; Methotrexate/therapeutic use ; Retrospective Studies ; Treatment Outcome ; Valacyclovir ; Valine/analogs & derivatives ; Valine/therapeutic use ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.
Autorzy:: Narváez J; Department of Rheumatology, Hospital Universitario de Bellvitge-IDIBELL, Barcelona, Spain.
Díaz-Torné C; Rheumatology Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Magallares B; Rheumatology Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Hernández MV; Department of Rheumatology, Hospital Clínic de Barcelona-IDIBAPS, Barcelona, Spain.
Reina D; Deparment of Rheumatology, Hospital de Sant Joan Despí, Consorci Sanitari Integral, Barcelona, Spain.
Corominas H; Deparment of Rheumatology, Hospital de Sant Joan Despí, Consorci Sanitari Integral, Barcelona, Spain.
Sanmartí R; Department of Rheumatology, Hospital Clínic de Barcelona-IDIBAPS, Barcelona, Spain.
de la Serna AR; Rheumatology Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Llobet JM; Rheumatology Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Nolla JM; Department of Rheumatology, Hospital Universitario de Bellvitge-IDIBELL, Barcelona, Spain.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2015 Apr 01; Vol. 10 (4), pp. e0123392. Date of Electronic Publication: 2015 Apr 01 (Print Publication: 2015).
Typ publikacji:: Comparative Study; Journal Article
MeSH Terms:: Antibodies, Monoclonal, Humanized/*therapeutic use
Antirheumatic Agents/*therapeutic use
Arthritis, Rheumatoid/*drug therapy
Isoxazoles/*therapeutic use
Methotrexate/*therapeutic use
Aged ; Antibodies, Monoclonal, Humanized/adverse effects ; Dose-Response Relationship, Drug ; Drug Therapy, Combination ; Female ; Humans ; Isoxazoles/adverse effects ; Leflunomide ; Male ; Methotrexate/adverse effects ; Middle Aged ; Neutropenia/chemically induced ; Retrospective Studies ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis.
Autorzy:: Bichler J; German Centre for Paediatric and Adolescent Rheumatology , Garmisch-Partenkirchen , Germany.
Benseler SM
Krumrey-Langkammerer M
Haas JP
Hügle B; Pokaż więcej
Źródło:: Scandinavian journal of rheumatology [Scand J Rheumatol] 2015; Vol. 44 (4), pp. 280-3. Date of Electronic Publication: 2015 May 20.
Typ publikacji:: Comparative Study; Journal Article
MeSH Terms:: Antirheumatic Agents/*therapeutic use
Arthritis, Juvenile/*complications
Isoxazoles/*therapeutic use
Methotrexate/*therapeutic use
Uveitis/*drug therapy
Uveitis/*etiology
Child ; Child, Preschool ; Chronic Disease ; Cohort Studies ; Dose-Response Relationship, Drug ; Drug Therapy, Combination ; Female ; Humans ; Infant ; Leflunomide ; Male ; Recurrence ; Retrospective Studies ; Time Factors ; Treatment Outcome ; Tumor Necrosis Factor-alpha/antagonists & inhibitors

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Nimesulide improves the symptomatic and disease modifying effects of leflunomide in collagen induced arthritis.
Autorzy:: Al-Abd AM; Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Al-Abbasi FA; Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
Nofal SM; Department of Pharmacology, Medical Division, National Research Centre, Giza, Egypt.
Khalifa AE; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Williams RO; Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom.
El-Eraky WI; Department of Pharmacology, Medical Division, National Research Centre, Giza, Egypt.
Nagy AA; Department of Forensic Medicine and Clinical Toxicology, Faculty of Medicine, Tanta University, Egypt.
Abdel-Naim AB; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2014 Nov 06; Vol. 9 (11), pp. e111843. Date of Electronic Publication: 2014 Nov 06 (Print Publication: 2014).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antirheumatic Agents/*administration & dosage
Arthritis, Experimental/*drug therapy
Arthritis, Rheumatoid/*drug therapy
Isoxazoles/*administration & dosage
Sulfonamides/*administration & dosage
Animals ; Arthritis, Experimental/pathology ; Arthritis, Rheumatoid/pathology ; Drug Synergism ; Drug Therapy, Combination ; Leflunomide ; Male ; Mice ; Severity of Illness Index ; Treatment Outcome